Long Term Use of Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration.
Tedi BegajDaeun JeongJong G ParkMargaret M RunnerAntonio CaponeA Bawa DassKimberly A DrenserLisa J FaiaNathan D FarleyBruce R GarretsonTarek S HassanTamer H MahmoudAlan MargherioPaul V RaphaelianSandeep RandhawaAlan J RubyScott SneedPrethy RaoJeremy D WolfeGeorge A WilliamsPublished in: Retina (Philadelphia, Pa.) (2023)
The nAMD cohort herein received on average 8 anti-VEGF injections per year for approximately 8 years; eyes with good (≥20/40) initial baseline vision maintained their VA while eyes with worse SCVA (≤20/50) had a robust initial improvement that diminished with time. Most patients were maintained on the same initial drug of choice and the rate of endo11phthalmitis was low.